Briumvi (Ublituximab-xiiy)



REFERRAL STATUS: New Referral Dose or Frequency Change Order Renewal Infusion Office Preference:

PATIENT INFORMATION			
Date: Patient Name:		DOB:	
□ NKDA Allergies:		Weight (lbs / kg): Height:	
Patient Status: 🗆 New to Therapy 🛛 Continuing Therapy - Last Tr		eatment Date:	Next Due Date:
PROVIDER INFORMATION			
		Office Email:	
5		Provider NPI:	
		City:	State: Zip:
Office Phone Number: Office Fax Number:			
DIAGNOSIS AND ICD 10 CODE			
Relapsing-Remitting Multiple		ICD-10 Code:	G35
Secondary Progressive Multiple Sclerosis		ICD-10 Code:	G35
REQUIRED DOCUMENTATION/Testing			
This signed order form by the provider		Labs and Tests supporting primary diagnosis	
Patient demographics AND insurance info		Hepatitis B Test Results: HBsAg & Total HepB Core	
□ Clinical/Progress notes supporting primary dx		Antibody	
Current MS treatment and end of current therapy date:			
PRE-MEDICATION ORDERS			
• • • •	l) PO 🗆 500mg 🗆 650mg 🗆 1000mg		Note: manufacturer
	dryl) PO / IV 🛛 25mg 🗆 50mg (if route	e is not circled PO will be	recommended
administered)) premedication regimen is Tylenol, Solu Medrol) IV [60mg [100 mg [mg			
	lu-Medrol) IV 🗆 60mg 🗆 100 mg 🗆	mg	Benadryl
□ other:			
MEDICATION ORDERS			
Initial Dosing	□ Briumvi 150 mg IV x 1 dose then 450 mg IV at week 2		
Maintenance Dosing	Briumvi 450 mg IV every 24 weeks		
Other Dosing :	Briumvimg IV		
Refills*: 🗆 None 🗆 X6 months 🗆 X1 year 💷 Other:			
*(if not indicated order will expire one year from date signed)			

SPECIAL INSTRUCTIONS

 $\hfill\square$ Urine pregnancy test prior to each infusion

Provider Name (Print)

Physician Signature:

Date:

Fax referral to 866-507-1164 or email to MICreferral@metroinfusioncenter.com

All information contained in this order form is strictly confidential and will become part of the patient's medical record. Revised 1/27/23